Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGC515 in advanced solid tumors
NCT06452160Phase 1Recruiting
- Sponsor
- BridGene Biosciences
- Start
- Jun 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BGC-515 in malignant mesothelioma, epithelioid hemangioendothelioma (EHE) and solid tumor (2 arms), sponsored by BridGene Biosciences. Primary endpoints: Incidence of adverse events (AEs) and serious adverse events (SAEs) at 1 year, Dose-limiting toxicities at 24 days and 2 more. Started Jun 2024; status: recruiting.
02
Drugs
BGC-515
03
Conditions
malignant mesotheliomaepithelioid hemangioendothelioma (EHE)solid tumor
Beyond the preview
Go deeper on NCT06452160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06452160.